When Scans Stay Stable: How Progression‑Free Survival Reflects Survival in mCRPC

/in /by

At the 2026 American Urological Association (AUA) Annual Meeting, researchers showed that radiographic progression‑free survival (rPFS), the time from treatment start until scans show clear cancer progression or death, is a strong and meaningful reflection of overall survival in men with metastatic castration‑resistant prostate cancer (mCRPC). Using individual‑patient data from the large TALAPRO‑2 trial, they […]

Read more

Phase 3 PSMAddition Trial Reports Positive Outcomes for mHSPC

/in , , /by

Results from the PSMAddition trial were published in a phase 3 setting and showed several clear numbers worth noting. The trial compared standard double hormone-based treatment alone (ADT + ARPI) versus the same treatment plus a PSMA-targeted radioligand therapy (Pluvicto), in men with metastatic hormone-sensitive prostate cancer.The biggest headline was a 58% lower risk of […]

Read more

ARASEC Trial Validates Darolutamide Plus ADT in Metastatic Hormone-Sensitive Prostate Cancer

/in , , /by

The ARASEC trial, offers compelling evidence for darolutamide combined with androgen deprivation therapy as a treatment option for men with metastatic hormone-sensitive prostate cancer. This Phase 2 study tackled a challenging ethical dilemma in modern clinical trial design: how to evaluate a new treatment when randomizing patients to receive only standard ADT would be considered […]

Read more

Telmisartan: A Familiar Blood Pressure Pill with New Potential in Cancer Therapy

/in , /by

Telmisartan, a widely used blood pressure drug, has shown unexpected promise as a booster for cancer treatment. Preclinical research indicates that when telmisartan is combined with the PARP inhibitor olaparib, cancer cells accumulate more DNA damage and become more vulnerable to treatment, even if they do not carry the usual BRCA‑type DNA repair defects that […]

Read more

Targeted Alpha Therapy Plus PARP Blockade: AZD2265 plus AZD9574 for Advanced Prostate Cancer

/in , , , /by

There is a new flexible trial for men with metastatic prostate cancer that has stopped responding to hormone therapy. Phase 1/2 PROSPECTOR trial tests three options: a PSMA‑targeted radioactive drug (AZD2265), the same drug combined with a PARP1 inhibitor (AZD9574), and standard docetaxel chemotherapy. The first part of the trial finds safe dose levels and […]

Read more

Phase 1 Trial: GTB-5550, Another B7-H3 NK-targeted Therapy for mCRPC

/in , , /by

GTB-5550 has begun Phase 1 clinical testing in solid tumors, marking the first patient dosing in a dose-escalation basket study. The trial is starting with prostate cancer, a setting where B7-H3 is reportedly highly expressed and where treatment options remain limited in the metastatic castration-resistant stage. The therapy is being delivered subcutaneously, which is notable […]

Read more

Phase 1 Trial: INR731 for mCRPC

/in , , /by

INR731 is an oral, investigational anticancer drug now entering first‑in‑human testing for men with metastatic castration‑resistant prostate cancer (mCRPC). It is being evaluated in a global, open‑label Phase 1 study with the primary goal of defining its safety, tolerability, pharmacokinetics, pharmacodynamics, and a recommended dose for further development, rather than demonstrating efficacy at this stage. […]

Read more

Phase 1/2 Trial for GDC‑1261 in Advanced Prostate Cancer

/in , , , /by

GDC‑1261 is a new study drug being tested in men with advanced or metastatic prostate cancer in a first‑in‑human Phase 1/2 trial. The public description of the study states that the main goals are to evaluate the safety profile, pharmacokinetics, and preliminary anti‑tumor activity of GDC‑1261 and to identify a recommended dose and dosing schedule […]

Read more